Vivos Therapeutics VVOS is set to give its latest quarterly earnings report on Monday, 2025-03-31. Here’s what investors need to know before the announcement.
Analysts estimate that Vivos Therapeutics will report an earnings per share (EPS) of $-0.43.
Vivos Therapeutics bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Performance in Previous Earnings
During the last quarter, the company reported an EPS beat by $0.30, leading to a 8.97% drop in the share price on the subsequent day.
Here’s a look at Vivos Therapeutics’s past performance and the resulting price change:
| Quarter | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|
| EPS Estimate | -0.7 | -1.05 | -1.90 | |
| EPS Actual | -0.4 | -0.60 | -1.63 | -3.05 |
| Price Change % | -9.0% | -5.0% | -12.0% | 4.0% |
Market Performance of Vivos Therapeutics’s Stock
Shares of Vivos Therapeutics were trading at $3.19 as of March 27. Over the last 52-week period, shares are down 10.98%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.
To track all earnings releases for Vivos Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Momentum26.16
Growth51.65
Quality–
Value65.32
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
